Research Progress of GABA Receptors in Alzheimer’s Disease / 中国生物化学与分子生物学报

Alzheimer’s disease (AD) is a progressive neurodegenerative disease with the early symptom of A β plaque, tau hyperphosphorylation neuronal tangle formation in cells. At present, accumulated evidence shows that the changes of GABA receptors are closely related to AD. Some studies have shown that the expression level of each subunit of the GABA receptor changes in AD patients. Therefore, it is speculated that the changes of GABA subunits may be related to the pathogenesis of AD, but there is no better methods to improve AD by targeting GABA receptors. In order to further understand the relationship between the changes of GABA receptors and AD, this paper first reviewed the changes of GABA receptors in AD patients and animal models’ brains and found that there was differential expression in GABA(A) receptor subunits in AD patients. Then we summarized the changes of GABA receptor subunits in Alzheimer database. Based on the data, we found that a few GABA subunits had significant changes. The evidence shows that the change of GABA receptors alters the neural activity in the brain. Other studies have found that the treatment of mice with GABA receptor agonists and antagonists can improve the cognitive ability of mice. We hope that understanding the differential expression of GABA receptors in AD will provide a more accurate target for the treatment of AD.

Two-dimensional Nanomaterials against β-Amyloid in the Treatment of Alzheimer’s Disease / 中国生物化学与分子生物学报

Alzheimer’s disease (AD) is a prevalent progressive neurodegenerative disorder among the elderly. In the scientific community, the β-amyloid (Aβ) hypothesis is currently a widely-accepted model for AD pathogenesis. Removing Aβ, inhibiting Aβ aggregation and depolymerizing Aβ fibrils are proposed to provide useful strategies for the treatment of AD. However, most current drugs used for anti-Aβ therapy usually have inherent drawbacks that may limit their clinical applications. With the rise of nanotechnology nowadays, the application of two-dimensional nanomaterials in medicine has rapidly attracted much attention from researchers. Two-dimensional nanomaterials not only have excellent physical and chemical properties, as well as good biocompatibility, but also can easily cross either the cell membrane or blood-brain barrier. Recently, it has been found that many two-dimensional nanomaterials can inhibit Aβ aggregation or depolymerize Aβ fibrils by intermolecular interaction, near-infrared photothermal effect, photocatalytic oxidation, chelation of copper ions, drug delivery and other mechanisms, implying its great potential in treating AD. This review will focus on the research of graphene and graphene-like two-dimensional nanomaterials such as molybdenum disulfide, graphitic carbon nitride, and black phosphorus used for anti-Aβ therapy in the treatment of AD.

Therapeutic Potential of ?-Secretase in Alzheimer's Disease / 生物化学与生物物理进展

Alzheimer!s disease (AD) is one of the commonest neurodegenerative diseases affected mainly theelderly. AD is characterized by the formation of neuritic plaque in brain, which is composed mainly of extracellular?amyloid deposion, the A?. A?is deprived from serial hydrolysis of amyloid precursor protein (APP) by twosecretases, the ?and ?-secretase respectively. Alternatively, APP can also be sequential processed by ?-secretaseand ?-secretase, which not only preclude the formation of A?, but also generate a large ectodomain (sAPP?) whohas several neuroprotective properties. Thus the secondary processing pathway has become the focus of ADresearch. Many results have indicated that members of the adamalysin family of proteins, mainly the ADAM 10,ADAM 17 and ADAM 9, fulfill some of the criteria required of ?-secretase. Here the biological characteristics of?-secretase, its activity regulation and its potential function as targets for the treatment of AD were summerized.

Alzheimer's disease pathogenesis and apparent progress in genetic research / 中国药理学通报

This paper briefly describes the mechanism of neurochemical changes in AD,the roles of the epigenetics,the regulation of gene expression and the mechanism of epigenetics in SAD.On the basis of the basic study on the AD during the decades,researchers initially revealed the mystery of the unfathomable neurochemical changes attack on AD.Especially in recentyears,researchers summarized the abnormal protein expression on SAD into epigenetics disease.This achievement helps researchers point out the new and strategic direction on AD pathogenesis,prevention and control mechanism.With the understanding of biological characteristics of epigenetics,AD needs to be studied in depth.